Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 9/20 | 0.43 |
| ▸ | ALPL | P05186 | 7/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3296830 | 0.97 | CCR4 (0.43) | CCR4ALPLTP53ALDH1A1LMNA | |
| SCHEMBL3294499 | 0.93 | CCR4 (0.48) | CCR4ALPLTP53 | |
| SCHEMBL3298158 | 0.90 | CCR4 (0.48) | CCR4ALPLTP53 | |
| SCHEMBL3299498 | 0.89 | TP53 (0.47) | CCR4TP53LMNAHSD11B1 | |
| SCHEMBL3291427 | 0.88 | TP53 (0.48) | CCR4TP53LMNAHSD11B1 | |
| SCHEMBL3296404 | 0.87 | CCR4 (0.40) | CCR4ALPLTP53HSD11B1 | |
| SCHEMBL3292780 | 0.87 | CCR4 (0.36) | CCR4TP53ALDH1A1GAAHSD11B1 | |
| SCHEMBL3297199 | 0.86 | TP53 (0.47) | CCR4TP53LMNAHSD11B1 | |
| SCHEMBL3294125 | 0.85 | TP53 (0.48) | CCR4TP53LMNAHSD11B1 | |
| SCHEMBL3298051 | 0.85 | CCR4 (0.53) | CCR4TP53HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100266539-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-7732442-B2 | Chemokine receptor antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1661889-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266539-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | CCR5, CCR4, CCR1 | CCR4 2/4885ALPL 2930/4885TP53 2581/4885 |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | CCR5, CCR4, CCR1 | CCR4 2/4885ALPL 2930/4885TP53 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.